Melbourne Masterclass Access Request
Search Sirtex AU
SIRT Approved for Routine Commissioning on the NHS
NHS England have announced that selective internal radiation therapy (SIRT) using yttrium-90 microspheres will be routinely commissioned for NHS patients with advanced colorectal cancer that has spread to the liver and is not responding to standard chemotherapies. The treatment will be available from April 2019.
Liver cancer: Selective Internal Radiation Therapy with SIR-Spheres® microspheres reimbursed in France
SIR-Spheres Y-90 resin microspheres will be reimbursed in France by the Health insurance for the treatment of selected patients with HCC. This decision results from the approval received from the Commission Nationale d'Évaluation des Dispositifs Médicaux et des Technologies de Santé (CNEDiMTS) on November 6th, 2018, which concluded that SIRT with SIR-Spheres had a therapeutic benefit in this disease. The reimbursement of SIR-Spheres will be effective from 20 March 2019 on.
New Analysis Reveals First-Line Treatment Data on SIR-Spheres® Y-90 Resin Microspheres for Patients with Liver Metastases from Right-Sided Primary Colon Cancer
SIRFLOX and FOXFIRE Global findings suggest that adding liver-directed Selective Internal Radiation Therapy (SIRT) to standard first-line chemotherapy may improve overall survival in metastatic colorectal cancer (mCRC) patients with right-sided primary tumours, compared to those receiving chemotherapy alone
FOXFIRE Combined Analysis Results in First-Line Treatment of Metastatic Colorectal Cancer Presented at ASCO
Overall Survival (OS) findings reviewed in detail; Potential median OS benefit in mCRC patients with right-sided primary colon cancer
SIR-Spheres® Y-90 Resin Microspheres Showed no Significant Difference in Overall Survival (OS) Compared to Sorafenib in Advanced HCC with Significantly Fewer Severe Adverse Events, New Asia-Pacific Study Finds
For the second time in less than two months, a major head-to-head study has shown that SIR-Spheres Y-90 resin microspheres, administered once directly to the liver offers important treatment benefits compared to twice-daily oral doses of sorafenib, the current standard of care for advanced hepatocellular carcinoma (primary liver cancer or HCC).
Metastatic colorectal cancer patients treated first-line with SIR-Spheres® Y-90 resin microspheres more likely to become candidates for potentially curative liver surgery, REsect study shows
Surgeons' blinded assessment of pre- and post-treatment CT scans of patients with previously unresectable colorectal cancer liver metastases treated in the SIRFLOX study presented at 12th Annual European-African HPB meeting.
NCCN Guidelines® Recommend SIR-Spheres® Y-90 Resin Microspheres for the Treatment of Metastatic Colorectal Cancer
Expert panel reaches uniform consensus that yttrium-90 microspheres is an appropriate option for patients with colorectal liver metastases.
Patients with Colorectal Cancer Liver Metastases Had Significantly Greater Depth of Tumour Response to SIR-Spheres® Y-90 resin microspheres, New SIRFLOX Analysis Shows
New data presented by Prof. Dr. Volker Heinemann in an oral abstract session at the European Society of Medical Oncology's 18th World Congress on Gastrointestinal Cancer suggest that patients with liver-dominant mCRC treated first-line with the combination of mFOLFOX6 and SIR-Spheres Y-90 resin microspheres in the recently published SIRFLOX study experienced a much more profound response to treatment in the liver than those who received chemotherapy alone.
Leading South African Health Insurer Approves Reimbursement of SIR-Spheres® Y-90 resin microspheres
Discovery Health, the leading South African private health insurer, has agreed to reimburse SIR-Spheres Y-90 resin microspheres for the treatment of all forms of inoperable liver tumours.
SIR-Spheres® Y-90 resin microspheres Are a Well-Tolerated Alternative to Standard Therapies for Inoperable Primary Liver Cancer, New UK NICE Medtech Innovation Briefing Says
Sirtex (ASX:SRX) announced today that the UK National Institute for Health and Care Excellence (NICE) has issued a new Medtech Innovation Briefing (MIB) stating that NHS doctors and commissioners may consider SIR-Spheres Y-90 resin microspheres as an alternative to standard therapy with trans-arterial chemoembolization (TACE) or sorafenib in the treatment of patients with inoperable primary liver cancer (hepatocellular carcinoma or HCC).
Netherlands Healthcare Institute Approves Reimbursement of Selective Internal Radiation Therapy (SIRT)
The Netherlands Healthcare Institute, Zorginstituut Nederland (ZIN), has agreed to reimburse Selective Internal Radiation Therapy (SIRT) for patients with colorectal liver metastases who have failed on or are intolerant to prior chemotherapy.
SIRFLOX Study Published in Journal of Clinical Oncology
Prestigious ASCO Journal Publishes 530-patient SIRFLOX Study on SIR-Spheres® Y-90 resin microspheres in the Management of Metastatic Colorectal Cancer (mCRC)
Treatment Results of SIR-Spheres® Y-90 Resin Microspheres are Similar Regardless of Patient Age, New Publication Shows
606-patient MORE Study Sub-Group Analysis Examined Outcomes for Elderly (≥70 years) and Very Elderly (≥75 years) Patients with Liver-Dominant Metastatic Colorectal Cancer (mCRC)
New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer
Adding SIR-Spheres® Y-90 resin microspheres to first-line chemotherapy for patients with unresectable metastatic colorectal cancer in the liver (mCRC) further extends Progression-Free Survival in that organ
SIRFLOX Study Presented at ASCO 2015 Annual Meeting
Clinical investigators cite significance of 7.9 month improvement in Progression-Free Survival in the liver for patients with unresectable metastatic colorectal cancer (mCRC) treated first line with SIR-Spheres® Y-90 resin microspheres plus chemotherapy
Sirtex Reports Preliminary SIRFLOX Study Results
In the first-line treatment of non-resectable metastatic colorectal cancer: SIRFLOX study does not show a statistically significant improvement in overall Progression-Free Survival. SIRFLOX study does show a statistically significant improvement in Progression-Free Survival in the liver. Data to be submitted for peer review to the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting.
FOXFIRE Global Study Completes Patient Recruitment
Sirtex Medical Limited (ASX:SRX) is pleased to announce the completion of patient recruitment in the FOXFIRE Global randomised controlled clinical study comparing SIR-Spheres®Y-90 resin microspheres in combination with standard of care chemotherapy versus chemotherapy alone in first - line metastatic colorectal cancer (mCRC)in patients with inoperable liver metastases.
NHS Wales approves funding for SIR-Spheres® (Y-90 resin microspheres) – an innovative form of internal radiotherapy for liver tumours – to patients in Wales under a new scheme
NHS Wales announced that Selective Internal Radiation Therapy (SIRT) will be made available to eligible patients in Wales with liver cancer that has spread from the bowel or bile duct cancer. NHS Wales has confirmed that they will join the Commissioning Through Evaluation (CtE) process to enable access for patients to SIRT and provide central funding to support this.
SIR-SPHERES® Y-90 resin microspheres recommended in new European Society of Medical Oncology (ESMO) Clinical Guidelines for treating metastatic colorectal cancer (mCRC)
Newly published European Society for Medical Oncology (ESMO) clinical guidelines for the treatment of metastatic colorectal cancer (mCRC) endorse radioembolisation, specifically with Yttrium-90 resin microspheres, as a clinically proven technology to "prolong time to liver tumour progression" in mCRC patients who have failed to respond to available chemotherapy options.
Data Presented at ASCO-GI Symposium Provides New Insights into Predicting SIR-Spheres® microspheres Treatment Outcomes
Researchers point to the role of pre-treatment laboratory tests and new modeling technology for enhancing delivery of treatment
NHS Approves Funding in 10 hospitals for Life-extending Liver Tumour Radiotherapy
Selective Internal Radiation Therapy (SIRT) is First Treatment Available Through New NHS Policy to Improve Access to Innovative Therapies
NHS England Makes SIRT (Selective Internal Radiation Therapy) First Treatment Available Through New Commissioning Through Evaluation Initiative
NHS Revision of Clinical Policy Commissioning Statement on SIRT will Allow Patients in England with Metastatic Colorectal Cancer (mCRC) and Intrahepatic Cholangiocarcinoma (ICC) who may Benefit from SIR-Spheres® microspheres to get Treatment in Specialist NHS Centres
Innovative Cancer Treatment Supported by NICE
New UK Guidance Should Improve Patient Access to SIR-SPHERES® Microspheres for Primary Liver Cancer
Large U.S. Multi-Center Study Supports the Safety and Efficacy of Sirtex's SIR-Spheres® microspheres in Treating Colorectal Liver Metastases
SAN FRANCISCO (Jan. 22, 2013) –– The results of a large multi-center clinical study re- affirming the safety and efficacy of Selective Internal Radiation Therapy (SIRT) with SIR- Spheres® microspheres in patients with metastatic colorectal cancer were presented today at the American Society of Clinical Oncology's 2013 Gastrointestinal Cancers Symposium.
Large U.S. Multi-Center Study Confirms Safety and Efficacy of SIR-Spheres® microspheres in More Than 600 Patients with Unresectable Liver Metastases
SIR-Spheres® microspheres are well-tolerated and effective internal radiotherapy for unresectable, heavily pre-treated colorectal cancer liver metastases, according to results from a new study of more than 600 patients presented today at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting. The data were presented by lead investigator Andrew Kennedy, M.D., FACRO, from Cancer Centers of North Carolina and North Carolina State University.[1]
Study Establishes Safety and Clinical Benefit of SIR-Spheres® microspheres in Treating Metastatic Liver Tumors in Patients who Failed Systemic Chemotherapy
SIR-Spheres® microspheres are safe and provide clinical benefit for patients with colon cancer liver metastases who have previously received liver-directed and systemic chemotherapy, according to the results of a prospective clinical study announced today at the Society of Interventional Radiology's
Fox Chase Cancer Center Study Evaluating the Safety of Concurrent Chemotherapy and Selective Internal Radiation Therapy using SIR-Spheres® Microspheres Released at 2011 American Society of Clinical Oncology Annual Meeting
Sirtex, a leading developer and manufacturer of targeted, innovative liver cancer therapies, today announced the results of a Phase I study evaluating the safety and efficacy of concurrent treatment using capecitabine in combination with Selective Internal Radiation Therapy (SIRT), also known as radioembolization, using SIR-Spheres® microspheres to treat liver tumors.
Study Evaluating SIR-Spheres® Microspheres in Patients with Metastatic Breast Cancer Presented at the 2011 American Society of Clinical Oncology Annual Meeting
Sirtex, a leading developer and manufacturer of targeted, innovative liver cancer therapies, today announced the results of a five-year study evaluating the tolerability, efficacy and survival rates of Selective Internal Radiation Therapy (SIRT), also known as radioembolization, using SIR-Spheres® microspheres in patients with liver metastases from breast cancer that are refractory to chemotherapy. The study was led by Roberto Cianni, M.D., interventional radiologist at Santa Maria Goretti Hospital in Latina, Italy.
Studies Reconfirm Significant Benefits Regarding the Use of SIR-Spheres® Microspheres for the Treatment of Inoperable Liver Tumors
Sirtex Announces Latest Clinical Findings and Provides Updates on Research Initiatives
Independent Multicentre Study Confirms Substantial Survival Benefit from SIR-Spheres Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy
Sydney- June 3, 2008- SIR-Spheres microspheres provides a substantial clinical benefit for patients with colorectal cancer that has spread to the liver and who have also failed available chemotherapy options, according to the results of an independent, prospective, multicentre phase II study conducted by the Italian Society ofLocoregional Therapies In Oncology (SITIL0).[1] The results of the study were reported today at the American Society of Clinical Oncology (ASCO) conference held in Chicago, 30 May to 3 June 2008.[1]
Sirtex Announces First Randomised Trial Evaluating Sir-Spheres Microspheres for Treatment of Inoperable Primary Liver Cancer
Sirtex Medical to sponsor FAST clinical trial
Update on Clinical Trial Evaluating SIR-Spheres Microspheres with Bevacizumab and Chemotherapy as a First-Line Treatment for Unresectable Metastatic Colorectal Cancer
Final Results of Clinical Trial Combining SIR-Spheres® microspheres with Chemotherapy in Patients with Inoperable Liver Metastases from Colorectal Cancer Published in Journal of Clinical Oncology
Sirtex Supports the First Pilot Study Evaluating SIR-Spheres® Microspheres in Combination with Bevacizumab and Chemotherapy as a First Line Treatment for Metastatic Colorectal Cancer
Prospective Multi-Center Trial to Evaluate Safety and Tolerability of Combination Therapies in Patients with Advanced Liver Disease
Repeated Treatments of SIR-Spheres® Microspheres Appear to be Safe for Patients with Metastatic Liver Tumors
Retrospective Analysis Presented at the 2007 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
New Clinical Trials Announcement
Sirtex and SIRT
Investigator Bios
W8-AU-0214
This content is intended for journalists only
By clicking "Yes" you are confirming that you are a journalist. If you are not a journalist, then please click "Go to Homepage" which will direct you to the Sirtex homepage.
Yes Go to Homepage